News

We are excited to announce that we will be presenting at the 3rd Antigen-Specific Immune Tolerance Drug Development conference.  We will be discussing AnTolRx's antigen-specific nanoformulation platform for the treatment of autoimmune diseases! Come join us in Boston...

We are excited to attend the 38th annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 13th through the 16th.

We will be attending the symposium "New Frontiers in Therapies for Celiac Disease". Join us at the University of Chicago (Chicago, IL) on November 23, 2019.

Psoriasis is an autoimmune disease that affects over 125 million people worldwide, that is up to 3% of the total population! At AnTolRx, our targeted approach actively promotes immune tolerance by inducing an anti-inflammatory phenotype and thus better treat disease....

We will be presenting data on AnTolRx's antigen-specific nanoformulation platform. Join us in Woods Hole, MA, on October 12-13th, 2019. http://www.newenglandimmunology.org

Dr. Sara Tezza will be presenting data on AnTolRx's antigen-specific nanoformulation platform. Join us in Boston March 26-28, 2019. http://as-immunetolerance.com

We are excited to attend this year's 37th annual JP Morgan Healthcare conference in San Francisco, CA this Monday January 7th through the 10th.

World Vaccine Congress Investor Panel, April 4th “…..Mr Carthy commented that “antigen specific tolerance has the potential to deliver disease modifying therapy for  indications including autoimmune, allergies and protein drug antibody reactions. AnTolRx has...

Dr. Francisco J Quintana will be presenting data on AnTolRx's antigen-specific nanoparticle platform. Join us in Boston April 24-26, 2018. http://as-immunetolerance.com

We are excited to attend the 36th annual JP Morgan Healthcare Conference in San Francisco, CA from January 8th-11th, 2018.